Patient Discovery

Cover Block

PUBLIC

Name	Patient Discovery
Tagline	A healthcare technology platform for oncology practices to manage patient needs and social determinants of health. [Patient Discovery, retrieved 2024]
Headquarters	Newton, United States
Founded	2016
Stage	Series A
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Series A (total disclosed ~$8,350,000)

Links

PUBLIC

• Website: https://www.patientdiscovery.com/
• LinkedIn: https://www.linkedin.com/company/patient-discovery

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn page.

Executive Summary

PUBLIC Patient Discovery is a healthcare technology company building a software platform to capture and operationalize the non-medical factors that influence patient outcomes, a focus that places it at a critical intersection of value-based care and health equity. Founded in 2016, the company targets oncology practices and health systems with its primary product, Companion by Patient Discovery™, which centralizes the collection of patient-reported experiences and social determinants of health (SDoH) data into clinical workflows [Patient Discovery, retrieved 2024]. The founding impetus came from the personal caregiver experiences of its co-founders, who sought to bring patient-reported barriers to the forefront of clinical decision-making [AQP Search, retrieved 2024].

Its differentiation rests on integrating patient engagement, care coordination, and revenue cycle management into a single solution, aiming to improve appointment productivity and documentation for reimbursements while addressing health disparities [Patient Discovery, retrieved 2024]. CEO Norm Shore, a healthcare technology entrepreneur, leads a team that includes former Boston Children's Hospital CEO Sandra Fenwick on its board, lending significant credibility in pediatric and academic medical circles [PR Newswire, 2022].

The company has raised capital across multiple rounds, with PitchBook reporting a total of $8.35 million, including a $2 million Series A round in April 2025 [PitchBook, retrieved 2024]. Operating on a SaaS model, its near-term trajectory will be defined by its ability to convert its clear mission into named enterprise deployments and demonstrate that its workflow platform can drive measurable improvements in both clinical outcomes and practice economics.

Data Accuracy: YELLOW -- Core product and team details are confirmed by company sources; funding totals are reported but conflict between PitchBook and TheCompanyCheck.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	~$8,350,000 (estimated)

Company Overview

PUBLIC

Patient Discovery Solutions Inc. was founded in 2016 in Newton, Massachusetts, a suburb of Boston, with a mission to integrate patient-reported experiences and social barriers into clinical workflows [Patient Discovery, retrieved 2024]. The founding story, as described by CEO Norm Shore, is rooted in personal caregiving experiences; he notes that "all three of us were driven by our own personal experiences as caregivers," though the identities of the other two co-founders are not detailed in public materials [AQP Search, retrieved 2024]. The company's legal entity is Patient Discovery Solutions Inc., and it has operated under the Patient Discovery brand since inception [Crunchbase, retrieved 2024].

Key milestones follow a steady, multi-year development path. The company closed its first significant seed round in late 2017, raising $3.6 million to begin building its platform [PitchBook, retrieved 2024]. By 2024, the leadership team expanded with strategic hires, including the appointment of Robyn Hayes as Vice President of Health Solutions and Sandra Fenwick, the former CEO of Boston Children's Hospital, to its board of directors [Patient Discovery, retrieved 2024] [PR Newswire, 2022-01-13]. The most recent publicly disclosed milestone is a $2 million Series A financing round completed in April 2025, which the company stated would be used to advance its oncology care and social determinants of health integration efforts [LeadsOnTrees, retrieved 2024].

Data Accuracy: YELLOW -- Core founding details and recent funding are confirmed, but co-founder identities and some historical financial figures have conflicting reports.

Product and Technology

MIXED

Patient Discovery's product suite is anchored by its patient needs-management and engagement platform, which the company markets under two names: Companion by Patient Discovery™ and the Patient Discovery Platform [Patient Discovery, retrieved 2024]. The core proposition is to collect real-world patient experiences and non-medical factors, particularly social determinants of health, before and between clinical visits [Patient Discovery, retrieved 2024]. This data is then centralized into a workflow tool designed for use by an entire care team, including non-clinical staff, to manage patient needs and barriers to care [Patient Discovery, retrieved 2024].

The platform's functional scope appears to integrate several adjacent workflows. According to the company, it combines care coordination, patient engagement, and revenue cycle management into a single solution aimed at streamlining patient support [Patient Discovery, retrieved 2024]. PitchBook describes it as an AI-based patient well-being platform that helps patients organize thoughts before appointments, supports personalized services and education, and aims to improve appointment productivity and health equity [PitchBook, retrieved 2024]. The technology stack is not explicitly detailed in public sources, but the reference to an AI-based platform and the nature of the data processing involved suggest a reliance on machine learning for patient risk stratification and workflow automation (inferred from product claims).

Data Accuracy: YELLOW -- Product features are confirmed by the company website and a secondary source, but technical architecture and implementation details are not publicly disclosed.

Market Research

PUBLIC The market for software that addresses social determinants of health (SDoH) in clinical settings is expanding, driven by a combination of regulatory pressure, a push for value-based care, and a growing recognition that non-medical factors are critical to patient outcomes.

Total addressable market figures specific to oncology-focused SDoH platforms are not publicly available from cited sources. However, the broader market for healthcare software addressing SDoH and patient engagement provides a relevant analog. According to PitchBook, the company is positioned within the AI-based patient well-being platform segment, which targets health systems, life sciences organizations, and health plans [PitchBook, retrieved 2024]. The demand is anchored in oncology, where complex treatment regimens and significant side effects make systematic tracking of patient-reported needs particularly valuable for care coordination and clinical trial support.

Several demand drivers are clear from the cited positioning. The shift toward value-based reimbursement models creates financial incentives for providers to document and address barriers to care, such as transportation or food insecurity, which the Patient Discovery Platform is designed to manage [Patient Discovery, retrieved 2024]. Concurrently, health equity initiatives, both internal to health systems and mandated by payers, are formalizing the collection of SDoH data. The company's focus on centralizing this workflow for entire care teams, including non-clinical staff, aligns with operational efforts to scale these initiatives without overburdening clinicians [Patient Discovery, retrieved 2024].

Key adjacent markets include general patient engagement software, population health management platforms, and specialty-specific electronic health record (EHR) modules. The company's wedge appears to be the integration of SDoH-specific workflow and documentation directly into the oncology care pathway, rather than operating as a standalone wellness app or a broad population health tool. Regulatory forces, such as CMS's requirements for screening patients for health-related social needs, act as a persistent tailwind, though the specific compliance burden and reimbursement codes are subject to change.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous segments; demand drivers are corroborated by company positioning and industry context.

Competitive Landscape

MIXED Patient Discovery enters a fragmented market by focusing its workflow and data capture tools exclusively on the oncology care setting, a niche with distinct operational and reimbursement pressures.

No named competitors were identified in the available public sources, making a direct head-to-head comparison table impossible. The competitive analysis must therefore be mapped by segment and function.

• Incumbent EHR and practice management systems. The primary competitive backdrop is the entrenched electronic health record (EHR) used by oncology practices. These systems, from vendors like Epic and Cerner, are the system of record for clinical data but are not designed for proactive, longitudinal capture of patient-reported experiences and social determinants of health (SDoH) between visits. Patient Discovery's wedge is to sit alongside the EHR, aggregating non-clinical data that the core system often misses and routing it into care team workflows.
• Point solutions for patient engagement and SDoH. A second segment includes standalone digital health companies offering patient engagement platforms, remote monitoring tools, or SDoH screening questionnaires. These tools can be generic across specialties or focused on chronic conditions like diabetes or heart failure. Patient Discovery's differentiation rests on its oncology-specific workflow integration, which ties patient-reported data directly to oncology care coordination and revenue cycle management tasks, a linkage less common in generalist platforms.
• Adjacent substitutes. The most significant adjacent competition may come from internal build efforts. Larger health systems or oncology networks with substantial IT resources could attempt to develop similar functionality within their existing EHR frameworks or through custom applications. The value proposition for an external vendor like Patient Discovery hinges on the speed of deployment, pre-built oncology-specific content, and the avoidance of internal development costs.

The company's most defensible edge today appears to be its focused domain expertise in oncology operations and its early integration of SDoH data with reimbursement workflows. This edge is informed by founder Norm Shore's stated caregiver experience in cancer care [AQP Search, retrieved 2024]. However, this edge is perishable. It is primarily a first-mover and product-design advantage in a niche, not protected by significant data network effects or regulatory barriers. A well-funded competitor with a broader patient engagement platform could decide to build or acquire oncology-specific modules, eroding this focus.

Patient Discovery is most exposed on two fronts. First, it lacks the distribution scale and capital of large, horizontal health IT vendors. If a major EHR player decides to deeply integrate SDoH and patient-reported outcome tools as a native feature, they could use existing client relationships to bypass a point solution. Second, the company's reliance on oncology practices, while focused, also caps its total addressable market and makes it vulnerable to budget cycles within a single specialty that is itself consolidating.

The most plausible 18-month competitive scenario involves continued niche consolidation. A winner in this segment will be the company that successfully demonstrates that its platform not only improves patient care but also directly, and provably, increases practice revenue through better documentation and reimbursement. A loser will be any point solution that fails to move beyond a pilot project and prove its return on investment in a multi-site deployment, remaining a discretionary expense rather than a core operational system.

Data Accuracy: YELLOW -- Competitive mapping is inferred from product positioning and market structure; no direct competitor names are publicly cited in company materials or third-party profiles.

Opportunity

PUBLIC If Patient Discovery can establish its platform as the standard for capturing and operationalizing patient-reported needs in oncology, it could unlock a multi-billion dollar opportunity by improving both care quality and financial performance for healthcare providers.

The headline opportunity for Patient Discovery is to become the category-defining platform for patient-reported outcomes and social determinants of health (SDoH) in oncology care. This outcome is reachable because the company has already defined a specific wedge: focusing on the non-medical factors that directly impact patient health and provider reimbursement. The platform's stated goal is to centralize workflows for entire care teams, moving beyond simple patient surveys to become an essential operational layer within a practice [Patient Discovery, retrieved 2024]. Success here would mean the company's software becomes a default piece of infrastructure for any oncology group seeking to improve health equity and maximize value-based care reimbursements, a pressing need in a specialty with high costs and complex patient journeys.

Growth could follow several concrete paths, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Oncology Standard of Care	The platform becomes a reimbursable, mandated part of oncology patient intake and monitoring, similar to how EHRs became mandatory.	A major oncology association or payer (e.g., CMS) issues guidance or a new billing code specifically for SDoH assessment and management.	The company is already targeting oncology practices with a platform built for this specific workflow [Patient Discovery, retrieved 2024]. Regulatory pressure to address health equity is increasing.
Life Sciences Data Partnership	Pharmaceutical companies license Patient Discovery's aggregated, de-identified real-world data to inform drug development, clinical trials, and market access strategies.	A partnership is announced with a top-20 pharma company to use the platform's data for a specific therapeutic area.	The company lists life sciences organizations as a target customer for using aggregated patient insights [Patient Discovery, retrieved 2024]. Real-world evidence is a high-value asset in drug development.
Health Plan Integration	Health insurers embed the platform into their member portals and provider networks to identify at-risk members, close care gaps, and reduce total cost of care.	A regional or national health plan pilots the tool with a select network of oncology providers.	The platform is marketed to health plans to address barriers to equitable care [Patient Discovery, retrieved 2024]. Payers have a direct financial incentive to manage SDoH.

The compounding effect for Patient Discovery would be a classic data and workflow flywheel. Early adoption by oncology practices generates a proprietary dataset linking specific patient needs (e.g., transportation, food insecurity) to clinical outcomes and reimbursement success. This dataset becomes a moat, making the platform's routing and recommendation engines more accurate and valuable than a generic tool. Improved outcomes and reimbursement efficiency then attract more practices, which further enriches the dataset and strengthens the product's value proposition for adjacent buyers like life sciences firms and payers. The appointment of Sandra Fenwick, former CEO of Boston Children's Hospital, to the board suggests an early focus on building credibility within the healthcare establishment, a key ingredient for this flywheel to begin turning [PR Newswire, 2022].

Quantifying the size of a win is challenging without public revenue, but credible comparables exist. Publicly traded companies focused on real-world data and evidence, such as Verana Health or entities within larger health IT firms, often trade at significant revenue multiples based on their data asset value. If Patient Discovery executes on the "Oncology Standard of Care" scenario and captures a meaningful share of the U.S. oncology practice market, its platform could support an annual recurring revenue stream in the tens of millions of dollars. In a successful exit, acquisition multiples in healthtech SaaS frequently range from 10x to 20x revenue for companies with strong growth and strategic data assets. This suggests a potential outcome where the company achieves a valuation several times its current total raised capital, contingent on proving product-market fit and scaling adoption (scenario, not a forecast).

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated target markets and product positioning, which are well-documented. The growth scenarios are plausible extrapolations but lack specific, cited evidence of progressing partnerships or mandates. The comparable market analysis is inferred from broader sector trends rather than direct company metrics.

Sources

PUBLIC

1. [Patient Discovery, retrieved 2024] Patient Discovery , https://www.patientdiscovery.com/

2. [AQP Search, retrieved 2024] An Interview with Norm Shore - CEO of Patient Discovery , Unknown

3. [PitchBook, retrieved 2024] Patient Discovery 2026 Company Profile: Valuation, Funding & Investors | PitchBook , https://pitchbook.com/profiles/company/170290-54

4. [Crunchbase, retrieved 2024] Patient Discovery Solutions - Crunchbase Company Profile & Funding , https://www.crunchbase.com/organization/patient-discovery-solutions

5. [Patient Discovery, retrieved 2024] Patient Discovery appoints Robyn Hayes as VP Health Solutions - Patient Discovery Solutions, Inc. , https://www.patientdiscovery.com/patient-discovery-appoints-robyn-hayes-as-vp-health-solutions/

6. [PR Newswire, 2022-01-13] Sandra Fenwick Joins Patient Discovery's Board of Directors , https://www.prnewswire.com/news-releases/sandra-fenwick-joins-patient-discoverys-board-of-directors-301459987.html

7. [LeadsOnTrees, retrieved 2024] Patient Discovery Raises $2M in Series A Funding to rework Oncology Care and SDoH Integration , https://www.leadsontrees.com/news/patient-discovery-raises-2m-in-series-a-funding-to-rework-oncology-care-and-sdoh-integration